NS Partners Ltd Grows Holdings in Edwards Lifesciences Co. (NYSE:EW)

NS Partners Ltd boosted its position in Edwards Lifesciences Co. (NYSE:EW) by 2.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 208,641 shares of the medical research company’s stock after buying an additional 4,170 shares during the quarter. NS Partners Ltd’s holdings in Edwards Lifesciences were worth $13,768,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Prospera Private Wealth LLC acquired a new stake in shares of Edwards Lifesciences during the third quarter worth approximately $32,000. Premier Fund Managers Ltd acquired a new position in Edwards Lifesciences during the 3rd quarter worth $11,763,000. Avior Wealth Management LLC increased its position in shares of Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after purchasing an additional 308 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at about $5,303,000. Finally, Banque Cantonale Vaudoise lifted its position in shares of Edwards Lifesciences by 46.9% during the third quarter. Banque Cantonale Vaudoise now owns 81,111 shares of the medical research company’s stock worth $5,353,000 after purchasing an additional 25,886 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Up 0.4 %

Edwards Lifesciences stock opened at $70.20 on Wednesday. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The stock has a market cap of $41.40 billion, a price-to-earnings ratio of 10.13, a PEG ratio of 3.81 and a beta of 1.12. The company’s 50-day moving average price is $67.59 and its two-hundred day moving average price is $75.91. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting analysts’ consensus estimates of $0.67. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same quarter last year, the business earned $0.59 earnings per share. On average, analysts expect that Edwards Lifesciences Co. will post 2.57 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently weighed in on EW. UBS Group lowered their price objective on Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating for the company in a report on Tuesday, September 10th. Daiwa Capital Markets upgraded Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a research note on Wednesday, July 31st. Wolfe Research raised shares of Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a report on Monday, July 29th. Daiwa America cut shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 30th. Finally, Truist Financial decreased their price target on shares of Edwards Lifesciences from $71.00 to $70.00 and set a “hold” rating for the company in a report on Friday, October 25th. Seventeen investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences currently has a consensus rating of “Hold” and an average price target of $75.67.

Insider Activity

In related news, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the sale, the insider now directly owns 198,526 shares in the company, valued at approximately $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total value of $347,550.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,262,521.36. This represents a 9.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 40,000 shares of company stock worth $2,657,000 over the last 90 days. 1.27% of the stock is currently owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.